Protease-Activated Drug Development

被引：185
作者：
Choi, Ki Young [1 ]
Swierczewska, Magdalena [1 ,2 ]
Lee, Seulki [1 ]
Chen, Xiaoyuan [1 ]
机构：
[1] NIBIB, LOMIN, NIH, Bethesda, MD 20892 USA
[2] SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA
来源：
THERANOSTICS | 2012年 / 2卷 / 02期
基金：
美国国家卫生研究院;
关键词：
Protease; activatable probe; Alzheimer's disease; cancer; caspase; cathepsin; kallikrein; MMP; PSA; serine protease; aspartyl protease; PROSTATE-SPECIFIC ANTIGEN; ALBUMIN-BINDING PRODRUG; L-LEUCYL-DOXORUBICIN; SENSITIVE PHOTODYNAMIC AGENTS; COPOLYMER-BOUND ADRIAMYCIN; SQUAMOUS-CELL CARCINOMAS; TRANSGENIC MOUSE MODEL; BREAST-CANCER PATIENTS; HUMAN CATHEPSIN-B; MATRIX METALLOPROTEINASES;
D O I：
10.7150/thno.4068
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
In this extensive review, we elucidate the importance of proteases and their role in drug development in various diseases with an emphasis on cancer. First, key proteases are introduced along with their function in disease progression. Next, we link these proteases as targets for the development of prodrugs and provide clinical examples of protease-activatable prodrugs. Finally, we provide significant design considerations needed for the development of the next generation protease-targeted and protease-activatable prodrugs.
引用
收藏
页码：156 / 178
页数：23
相关论文
共 269 条
  • [1] Predicting biomarkers for ovarian cancer using gene-expression microarrays
    Adib, TR
    Henderson, S
    Perrett, C
    Hewitt, D
    Bourmpoulia, D
    Ledermann, J
    Boshoff, C
    [J]. BRITISH JOURNAL OF CANCER, 2004, 90 (03) : 686 - 692
  • [2] CHEMICAL ASPECTS OF SELECTIVE TOXICITY
    ALBERT, A
    [J]. NATURE, 1958, 182 (4633) : 421 - 423
  • [3] Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth doxorubicin with less toxicity
    Albright, CF
    Graciani, N
    Han, W
    Yue, E
    Stein, R
    Lai, ZH
    Diamond, M
    Dowling, R
    Grimminger, L
    Zhang, SY
    Behrens, D
    Musselman, A
    Bruckner, R
    Zhang, MZ
    Jiang, X
    Hu, D
    Higley, A
    DiMeo, S
    Rafalski, M
    Mandlekar, S
    Car, B
    Yeleswaram, S
    Stern, A
    Copeland, RA
    Combs, A
    Seitz, SP
    Trainor, GL
    Taub, R
    Huang, P
    Oliff, A
    [J]. MOLECULAR CANCER THERAPEUTICS, 2005, 4 (05) : 751 - 760
  • [4] Antibody-drug conjugates: targeted drug delivery for cancer
    Alley, Stephen C.
    Okeley, Nicole M.
    Senter, Peter D.
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2010, 14 (04) : 529 - 537
  • [5] The plasminogen activation system in tumor growth, invasion, and metastasis
    Andreasen, PA
    Egelund, R
    Petersen, HH
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (01) : 25 - 40
  • [6] Evolving role of uPA/uPAR system in human cancers
    Ass, Kathleen
    Ahmad, Aamir
    Azmi, Asfar S.
    Sarkar, Sarah H.
    Sarkar, Fazlul H.
    [J]. CANCER TREATMENT REVIEWS, 2008, 34 (02) : 122 - 136
  • [7] SYNTHESIS AND FUNCTIONAL-EVALUATION OF A PEPTIDE DERIVATIVE OF 1-BETA-D-ARABINOFURANOSYLCYTOSINE
    BALAJTHY, Z
    ARADI, J
    KISS, IT
    ELODI, P
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (18) : 3344 - 3349
  • [8] AMINO-ACID AND DIPEPTIDE DERIVATIVES OF DAUNORUBICIN .2. CELLULAR PHARMACOLOGY AND ANTI-TUMOR ACTIVITY ON L1210 LEUKEMIC-CELLS INVITRO AND INVIVO
    BAURAIN, R
    MASQUELIER, M
    DEPREZDECAMPENEERE, D
    TROUET, A
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1980, 23 (11) : 1171 - 1174
  • [9] Cysteine proteases as disease markers
    Berdowska, I
    [J]. CLINICA CHIMICA ACTA, 2004, 342 (1-2) : 41 - 69
  • [10] Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
    Bergers, G
    Brekken, R
    McMahon, G
    Vu, TH
    Itoh, T
    Tamaki, K
    Tanzawa, K
    Thorpe, P
    Itohara, S
    Werb, Z
    Hanahan, D
    [J]. NATURE CELL BIOLOGY, 2000, 2 (10) : 737 - 744
12345678910